The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2023 | Optimising radiotherapy for limited-stage SCLC
Bjørn Henning Grønberg, MD PhD, Norwegian University of Science and Technology, Trondheim, Norway, discusses recent developments in radiotherapy for limited-stage small cell lung cancer (LS-SCLC). Combination therapies comprising of radio- and chemotherapy have not been widely implemented for LS-SCLC due to logistical challenges, toxicity concerns, and the intensity of the recommended twice-daily regimen. Nevertheless, recent data generated from once- and twice-daily regimens of different strengths demonstrated a large improvement in median overall survival and an increase in 5-year survival rates. Dr Grønberg emphasises the need for new strategies to implement radiotherapy for LS-SCLC, such as acceleration of the treatment. This interview took place at the 2023 World Conference on Lung Cancer (WCLC) in Singapore, Singapore.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved
